



Know with confidence who will benefit from chemotherapy and who will not,
among women diagnosed with node-negative,
hormone-receptor positive, HER2-negative early stage
breast cancer^{1-3,5}

What is PCP?

PCP is a collaboration between Genomic Health and Medilinks to help alleviate the financial burden for patients who may be recommended chemotherapy based on their Oncotype DX Breast Recurrence Score[®] results.

What is the Oncotype DX Breast Recurrence Score test?

This is a genomic test performed on the breast tumour tissue to provide personalised information to help understand whether adding chemotherapy to your treatment regimen is likely to be beneficial.

What does the Recurrence Score[®] result mean to your treatment decision?

You and your physician will use your individual Recurrence Score result to more accurately assess the likely benefit of chemotherapy. Patients with a Recurrence Score result comprised between 26 and 100 will have substantial benefit from the addition of chemotherapy to hormone therapy. In the vast majority of patients with a Recurrence Score result of 0 to 25, adding chemotherapy will not reduce this risk.¹⁻⁴ Your physician will use the test result to tailor the appropriate treatment plan for you.

Who can benefit from the Oncotype DX[®] test?

Patients who are recently diagnosed with early stage invasive breast cancer that is hormone receptor-positive, HER2-negative, lymph node-negative¹⁻³, and where appropriate as advised by your physician, involving up to 3 positive lymph nodes.⁵⁻⁷

Who is eligible for PCP?

PCP is available only to patients who are resident in India (*foreign/visiting patients are excluded*), are undergoing treatment for their breast cancer in India, and have been referred by their treating physicians to order the Oncotype DX Breast Recurrence Score[®] test directly from Medilinks Inc.

The test can be ordered by contacting Customer Care at:



Tel: +91 8080901234
+91 22 4920 3000/1/2
Email: csmedilinks@medilinksinc.com

What is the process of PCP?

Patient contacts Medilinks via referral by treating physician in India to order the test



Patient submits to Medilinks the prescribed Patient Information Form, Histopathology Report, and Authorisation Letter for the Collection of Tissue Specimen Block



Patient pays Medilinks for the total cost of the test:

INR 320,000/-



Test result is made available to the ordering doctor in 2 weeks



Recurrence score result 25 and below

No refund



Recurrence score result 26 and above

INR 1,00,000/- refund of amount paid, in 45 days after report delivery date*

* Refund will be made based solely on the Recurrence Score result, regardless of the final treatment plan.

* In the unlikely event of test failure and the test result not being delivered, 97% refund will be made.

Medilinks reserves the right to terminate the programme at any time if or when warranted.

For more information about the Oncotype DX Breast Recurrence Score test, visit oncotypeIQ.com or contact **Medilinks Inc.**

References: 1. Paik et al *N Engl J Med*. 2004. 2. Paik et al. *J Clin Oncol* 2008. 3. Sparano *N Engl J Med*. 2018. 4. EBCTCG *Lancet*. 2012. 5. Albain et al. *Lancet Oncol*. 2010. 6. Dowsett et al. *J Clin Oncol*. 2010. 7. Nitz et al. *Breast Cancer Res Treat*. 2017.

Genomic Health, Oncotype DX Breast Recurrence Score, Oncotype DX, Recurrence Score, Oncotype IQ, Genomic Intelligence Platform and Making cancer care smarter are trademarks or registered trademarks of Genomic Health, Inc. © 2018 Genomic Health, Inc. All rights reserved. GH11302_1018_EN_IND